Inhibition of TBK1/IKKε mediated RIPK1 phosphorylation sensitizes tumors to immune cell killing
Anastasia Piskopou, David W Vredevoogd, Xiangjun Kong, Daniel S Peeper, Maarten Altelaar, Kelly E Stecker · 2025
Read Inhibition of TBK1/IKKε mediated RIPK1 phosphorylation sensitizes tumors to immune cell killing by Anastasia Piskopou, David W Vredevoogd, Xiangjun Kong, Daniel S Peeper, Maarten Altelaar, Kelly E Stecker (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12663160.txt.
Description
Anastasia Piskopou and co-authors block a protective signal to make tumors easier for immune cells to kill, in this 2025 study. Many cancers resist attack by killer T cells. That resistance blunts modern immunotherapy such as checkpoint blockade.
T cells use a cytokine signal to help destroy tumor cells. Some tumors mute that pathway and survive the attack. The team show that two kinases normally shield a death-linked protein from the signal. Blocking those kinases leaves the shield off, and tumors grow sensitive again. Pairing the blockers with immunotherapy could widen its reach. The work names a drug combination worth testing in patients. Safety checks will decide whether the pairing can reach trials.
Catalog record
| CREATOR | Anastasia Piskopou, David W Vredevoogd, Xiangjun Kong, Daniel S Peeper, Maarten Altelaar, Kelly E Stecker |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |